Opendata, web and dolomites

RheumArth SIGNED

New drug for the treatment of rheumatoid arthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RheumArth project word cloud

Explore the words cloud of the RheumArth project. It provides you a very rough idea of what is the project "RheumArth" about.

utmost    clinical    candidate    expectancy    renders    compliance    life    incidence    autoimmune    strategic    joints    indication    ensuing    ra    healthy    validate    instrument    molecule    preliminary    therapeutic    small    30    chronic    amounting    acute    self    innovation    inflammation    area    annual    effectiveness    positioning    quality    prepare    profile    chemically    unprecedent    generation    tolerance    sme    safety    treatment    patient    people    million    45billion    drugs    market    tissues    human    foreseen    foothold    modulating    1st    iia    disease    volunteers    decreased    treatments    arthritis    surrounding    company    mechanisms    alone    proportion    medium    supporting    context    mobilizing    trail    proof    therapies    proved    patients    drug    provider    variety    threatening    permanent    activation    ap1189    anti    first    synact    immune    disability    rheumatoid    causing    disorder    inflammatory    showing    efficacy    poc    position    synthesized    time    damage    severe    trials    combination    validation   

Project "RheumArth" data sheet

The following table provides information about the project.

Coordinator
SYNACT PHARMA APS 

Organization address
address: DRONNINGGARDS ALLE 136
city: HOLTE
postcode: 2840
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.synactpharma.com/sv/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYNACT PHARMA APS DK (HOLTE) coordinator 50˙000.00

Map

 Project objective

Rheumatoid arthritis (RA) is a chronic autoimmune disorder causing inflammation and permanent damage in joints and surrounding tissues - leading to severe disability, decreased quality of life, and reduced life expectancy. The disease affects more than 6 million people with annual costs amounting to €45billion in the Europe (EU) alone. There is a wide range of drug therapies for RA, mobilizing a variety of anti-inflammatory and immune modulating effects. However, a significant proportion (30%) of the patients do not respond to current treatments, efficacy is often reduced over time and the incidence of side effects is high and can be severe and life threatening. AP1189 is new chemically-synthesized small molecule drug for the treatment of Rheumatoid arthritis (RA). Through specific activation of the patients’ self-anti-inflammatory mechanisms, our first drug candidate renders unprecedent combination of safety, effectiveness and patient compliance, without the side effects associated with current therapies. The clinical validation of our drug for RA - 1st indication (foreseen for the Innovation Project) - will not only open a large market within this therapeutic area, as it will allow Synact to set a market foothold in the chronic inflammatory disease market, supporting the company´s medium term strategic positioning as an unique provider of a new generation of anti-inflammatory drugs. AP1189 clinical validation is on-going with current Phase I clinical trials showing promising preliminary results – safety and tolerance was proved in healthy human volunteers. Next step in the development will be a Phase IIa Proof-Of-Concept (POC) trail to validate our drug´s efficacy profile in RA patients. In this context, the present Phase 1 will be of utmost importance to validate AP1189´s market position and potential in RA and prepare the large clinical validation aimed for in the ensuing SME Instrument Phase II project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RHEUMARTH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RHEUMARTH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More